A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
A phase 3 trial of Pasritamig, Docetaxel and Prednisone in prostate cancer, run by Janssen Research & Development, LLC, now recruiting.
Overview
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer is a phase 3 interventional study registered as NCT07225946 by Janssen Research & Development, LLC, with 800 participants planned, started 2025-12-19 and due to reach its primary completion in 2027-11-19. Interventions recorded: Pasritamig, Docetaxel and Prednisone/Prednisolone.
Similar pages
not linked directly; found by shared links- TrialA Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
Shares Prednisone, Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialAn Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Shares Prednisone, Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialStudy of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialA Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Shares Prednisone, Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Shares Prednisone, Prostate cancer and the tag pipeline.
- TrialA Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialSubstudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Shares Prednisone, Docetaxel, Prostate cancer and the tag pipeline.